Fundraising Fox
Aurion Biotech
Seattle, US · Founded 2021 · Delaware corporation · 116 employees on LinkedIn · 3 known investors
Find your way into Aurion Biotech
Sign up to see every warm intro you have to Aurion Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aurion Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.
Founders & leadership
DR
DAVID ROSTOVChief Financial Officer2021–2024David Rostov is an executive at Aurion Biotech, a company developing regenerative cell therapies for corneal diseases. He brings experience in finance leadership, mergers and acquisitions, and fundraising across biotech and technology companies, with prior involvement in public and private board roles.
GK
GREG KUNSTNamed on SEC filing
PL
PATRICK LALLYNamed on SEC filing
JB
JEANNETTE BANKESNamed on SEC filing
CM
CHRISTINE MCCAULEYNamed on SEC filing
AL
ARNAUD LACOSTENamed on SEC filing
TF
TOM FRINZINamed on SEC filing
Board
LW
LINK WILLIAMBoard director
AE
Investors · 3
Visionary Ventureslisted by Visionary VenturesNewport Beach · $5M – $15M
How we know: Visionary Ventures's portfolio page · funding news · press coverage · Not right? Tell us
Deerfield Management CompanyreportedNew Yorkvia Andrew ElBardissi · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Flying L Partnersreported
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$81.4M disclosed across 3 rounds · 2022
▶$26.1MraisedApr 2022 · 2 investors · BiotechnologyRule 506(c)
▶$26.1MraisedApr 2022 · 2 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- JEANNETTE BANKESDirector
- LINK WILLIAMDirector
- GREG KUNSTExecutive Officer, Director
- PATRICK LALLYDirector
- ANDREW ELBARDISSIDirector
- ARNAUD LACOSTEExecutive Officer
- CHRISTINE MCCAULEYDirector
- DAVID ROSTOVExecutive Officer
- TOM FRINZIDirector
- Offering amount
- $26.1M
- Amount sold
- $26.1M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06c
▶$11KraisedApr 2022 · 32 investors · BiotechnologyRule 506(c)
▶$11KraisedApr 2022 · 32 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- GREG KUNSTExecutive Officer, Director
- PATRICK LALLYDirector
- JEANNETTE BANKESDirector
- LINK WILLIAMDirector
- DAVID ROSTOVExecutive Officer
- ANDREW ELBARDISSIDirector
- CHRISTINE MCCAULEYDirector
- ARNAUD LACOSTEExecutive Officer
- TOM FRINZIDirector
- Offering amount
- $11K
- Amount sold
- $11K
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06c
▶$55.3MraisedApr 2022 · 9 investors · BiotechnologyRule 506(c)
▶$55.3MraisedApr 2022 · 9 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- JEANNETTE BANKESDirector
- LINK WILLIAMDirector
- ANDREW ELBARDISSIDirector
- PATRICK LALLYDirector
- GREG KUNSTExecutive Officer, Director
- CHRISTINE MCCAULEYDirector
- DAVID ROSTOVExecutive Officer
- ARNAUD LACOSTEExecutive Officer
- TOM FRINZIDirector
- Offering amount
- $120.3M
- Amount sold
- $55.3M
- Sales commissions
- $4M
- Placement agents
- Raymond James
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
virionVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Companies working in the same space as Aurion Biotech.
In the news
Frequently asked questions
- What does Aurion Biotech do?
- Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.
- Who are Aurion Biotech's investors?
- Aurion Biotech's investors include Visionary Ventures, Deerfield Management Company, Flying L Partners.
- How much funding has Aurion Biotech raised?
- Aurion Biotech has disclosed $81.4M raised across 3 rounds.
- Where is Aurion Biotech headquartered?
- Aurion Biotech is headquartered in Seattle, US.